Display options
Cite
Young JW, Potter WZ, Riley S, et al. Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. Innov Clin Neurosci. 2015;12(3):5S-10S
Young, J. W., Potter, W. Z., Riley, S., Groeneveld, G. J., Kinon, B. J., Egan, M. F., & Feltner, D. E. (2015). Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. Innovations in clinical neuroscience, 12(3), 5S-10S.
Young, Jared W, et al. "Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium." Innovations in clinical neuroscience vol. 12,3 (2015): 5S-10S.
Young JW, Potter WZ, Riley S, Groeneveld GJ, Kinon BJ, Egan MF, Feltner DE. Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. Innov Clin Neurosci. 2015 Mar-Apr;12(3):5S-10S. PMID: 25977839; PMCID: PMC4571292.
Copy Download .nbib Format: NLM
Share it on

Innov Clin Neurosci. 2015 Mar-Apr;12(3):5S-10S.

Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.

Innovations in clinical neuroscience

Jared W Young, William Z Potter, Steve Riley, Geert J Groeneveld, Bruce J Kinon, Mike F Egan, Douglas E Feltner

Affiliations

  1. Dr. Young is with the Department of Psychiatry, University of California San Diego, La Jolla, California, and Research Service, VA San Diego Healthcare System, San Diego, California; Dr. Potter is with the National Institute of Mental Health, Rockville, Maryland; Dr. Riley is with the Department of Clinical Pharmacology, Global Innovative Pharma Business, Pfizer, Inc., Groton, Connecticut; Dr. Groeneveld is with Center for Human Drug Research, The Netherlands; Dr. Kinon is with Lundbeck LLC, Deerfield, Illinois (Dr. Kinon was with Eli Lilly and Company, Indianapolis, Indiana, when this material was presented); Dr. Egan is with Clinical Neuroscience, Merck & Co, Inc, North Wales, Pennsylvania; and Dr. Feltner is with AbbVie Inc. Pharmaceuticals, Chicago, Illinois.

PMID: 25977839 PMCID: PMC4571292

Abstract

For decades, there has been a distinct disconnect translating a compound's effects from basic neuroscience into clinical efficacy. This disconnect has not only been in terms of generating approved compounds, but also in rejecting targets. During the drug discovery process there are key points to be adhered to that would strengthen the likelihood of a compound being translated to the clinic. These points include 1) the importance of translational pharmacology whereby preclinical pharmacological data should predict clinical efficacy; 2) rigorous early phase drug evaluation to enhance early go/no-go decisionmaking; 3) using exposure response modeling to predict drug efficacy during proof-of-concept trials; 4) designing and conducting the appropriate proof-of-concept study; and 5) optimizing Phase II studies to set the stage for success in Phase III trials. These topics were covered in The International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn 2013 meeting on the topic of translational and early development strategies and tools led by Drs. Potter and Feltner. This report comprises a review of those proceedings with a concluding summary to advance future clinical trials.

Keywords: Drug discovery; FDA; decision-making; pharmacokinetics; pharmacology; proof of concept; target rejection

References

  1. Drug Discov Today. 2012 May;17(9-10):419-24 - PubMed
  2. Pain. 1988 Aug;34(2):117-22 - PubMed
  3. Dialogues Clin Neurosci. 2012 Mar;14(1):29-37 - PubMed
  4. Pharmacol Rep. 2012;64(6):1316-25 - PubMed
  5. Sleep Med. 2013 Oct;14(10):955-63 - PubMed
  6. Int J Neuropsychopharmacol. 2013 May;16(4):889-904 - PubMed
  7. Nat Rev Drug Discov. 2010 Nov;9(11):856-65 - PubMed
  8. Anesthesiology. 2005 Jul;103(1):130-9 - PubMed
  9. Curr Alzheimer Res. 2012 May;9(4):481-90 - PubMed
  10. Psychopharmacology (Berl). 2011 Dec;218(3):513-24 - PubMed
  11. Eur J Pain. 2001;5(3):267-77 - PubMed
  12. Mol Interv. 2006 Apr;6(2):77-88, 59 - PubMed
  13. Psychopharmacology (Berl). 2010 Jul;210(4):591-604 - PubMed
  14. Schizophr Res. 2013 May;146(1-3):224-30 - PubMed

Publication Types